Using Adalimumab to Treat Autoimmune Enteropathy

Area of Science:

• Gastroenterology
• Immunology
• Internal Medicine

Background:

• Autoimmune enteropathy (AIE) is a rare condition in adults characterized by severe diarrhea and malnourishment.
• Diagnosis relies on clinical, serologic, and histologic findings.
• Current treatments focus on nutritional support and immunosuppression, primarily corticosteroids.

Observation:

• A challenging case of adult-onset autoimmune enteropathy is presented.
• The patient exhibited refractory symptoms despite conventional therapies.

Findings:

• Successful treatment of autoimmune enteropathy was achieved using adalimumab.
• Adalimumab, an antitumor necrosis factor agent, demonstrated efficacy in this rare condition.

Implications:

• This case suggests adalimumab as a potential therapeutic option for refractory autoimmune enteropathy.
• Further research into biologic agents for AIE is warranted.
• Expanding treatment strategies may improve outcomes for patients with this infrequent disease.